The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cannabinoids control spasticity and tremor in a multiple sclerosis model
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Self-citationControl of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Pharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Self-citationThe Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis
Consroe, P., Musty, R., Rein, J., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 323
Self-citationHuffman, J. W., Liddle, J., Yu, S., Aung, M. M., Abood, M. E., Wiley, J. L., & Martin, B. R. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00219-9 · Cited by 288
Self-citationSR141716A is an inverse agonist at the human cannabinoid CB1 receptor
Landsman, R. S., Burkey, T. H., Consroe, P., Roeske, W. R., & Yamamura, H. I. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01160-6 · Cited by 262
Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis
Lyman, W. D., Sonett, J. R., Brosnan, C. F., Elkin, R., & Bornstein, M. B. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90075-1 · Cited by 200
The Functional Neuroanatomy of Brain Cannabinoid Receptors
Breivogel, C. S., & Childers, S. R. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0229 · Cited by 197
Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice
Baker, D., O'Neill, J. K., Gschmeissner, S. E., Wilcox, C. E., Butter, C., & Turk, J. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90019-j · Cited by 192
Self-citation
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Synergy research: approaching a new generation of phytopharmaceuticals.
Wagner, H., & Ulrich-Merzenich, G. (2009) · Phytomedicine · doi:10.1016/j.phymed.2008.12.018 · Cited by 1,296
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Synergy and other interactions in phytomedicines
WILLIAMSON, E. (2001) · Phytomedicine · doi:10.1078/0944-7113-00060 · Cited by 1,004
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Synergism between natural products and antibiotics against infectious diseases
Hemaiswarya, S., Kruthiventi, A. K., & Doble, M. (2008) · Phytomedicine · doi:10.1016/j.phymed.2008.06.008 · Cited by 916
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
History of Cannabis and Its Preparations in Saga, Science, and Sobriquet
Russo, E. B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790144 · Cited by 621
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I. P., Naylor, A., Bountra, C., Banati, R. R., & Anand, P. (2006) · BMC Neurology · doi:10.1186/1471-2377-6-12 · Cited by 509
New approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
“The endocannabinoid system has been shown to control spasticity in the animal models of the disease [9,17] and endogenous and exogenous cannabinoids have been shown to improve spasticity in such models, thereby providing a sound pharmacological basis for the treatment of spasticity with cannabinoids.”
BackgroundLigresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Self-citationWade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Molina-Holgado, E., Vela, J. M., Arévalo-Martı́n, A., Almazán, G., Molina-Holgado, F., Borrell, J., & Guaza, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09742.2002 · Cited by 419
Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study
GRANT, I., GONZALEZ, R., CAREY, C. L., NATARAJAN, L., & WOLFSON, T. (2003) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617703950016 · Cited by 411
Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051920 · Cited by 393
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S., & for the Sativex Spasticity in MS Study Group (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01639.x · Cited by 379
Endocannabinoids control spasticity in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., et al. (2001) · The FASEB Journal · doi:10.1096/fj.00-0399fje · Cited by 378
Self-citationCannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease
Kendall, D. A., & Yudowski, G. A. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00294 · Cited by 359
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
Self-citationCannabinoids inhibit neurodegeneration in models of multiple sclerosis
Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., et al. (2003) · Brain · doi:10.1093/brain/awg224 · Cited by 342
Self-citationCannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Núñez, E., Benito, C., Pazos, M. R., Barbachano, A., Fajardo, O., González, S., Tolón, R. M., & Romero, J. (2004) · Synapse · doi:10.1002/syn.20050 · Cited by 333
Cannabis, the mind and society: the hash realities
Murray, R. M., Morrison, P. D., Henquet, C., & Forti, M. D. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2253 · Cited by 322
Burns, H. D., Van Laere, K., Sanabria-Bohórquez, S., Hamill, T. G., Bormans, G., Eng, W.-S., Gibson, R., Ryan, C., Connolly, B., Patel, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703472104 · Cited by 315
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
Arévalo-Martı́n, Á., Vela, J. M., Molina-Holgado, E., Borrell, J., & Guaza, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02511.2003 · Cited by 314
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
The Blood-Brain Barrier and Its Role in Immune Privilege in the Central Nervous System
Pachter, J. S., de Vries, H. E., & Fabry, Z. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.6.593 · Cited by 294
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
Self-citationCannabinoid CB2 receptors in human brain inflammation
Benito, C., Tolón, R. M., Pazos, M. R., Núñez, E., Castillo, A. I., & Romero, J. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707505 · Cited by 291
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283
Evidence against the presence of an anandamide transporter
Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M., & Deutsch, D. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730816100 · Cited by 279
Huestis, M. A. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_23 · Cited by 278
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M., & Reif, M. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1048oa · Cited by 262
Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256
Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Croxford, J. L., & Yamamura, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.023 · Cited by 255
Self-citationCannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells
Klein, T. W., & Cabral, G. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-005-9007-x · Cited by 172
Therapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“The first such preclinical study demonstrated an amelioration of both tremor and spasticity in mice suffering from chronic relapsing EAE upon in vivo treatment with THC, methanandamide (a stable and non-hydrolizable AEA anolog), and synthetic CB1 or CB2 agonists (Baker et al., 2000).”
Animal models of multiple sclerosis: From rodents to zebrafish
Burrows, D. J., McGown, A., Jain, S. A., De Felice, M., Ramesh, T. M., Sharrack, B., & Majid, A. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518805246 · Cited by 135
Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V., & Docagne, F. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06377.x · Cited by 109
Bernal-Chico, A., Canedo, M., Manterola, A., Victoria Sánchez-Gómez, M., Pérez-Samartín, A., Rodríguez-Puertas, R., Matute, C., & Mato, S. (2015) · Glia · doi:10.1002/glia.22742 · Cited by 87
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Al-Izki, S., Pryce, G., O'Neill, J. K., Butter, C., Giovannoni, G., Amor, S., & Baker, D. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.09.001 · Cited by 73
Self-citationSativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7878-1 · Cited by 66
Pryce, G., Giovannoni, G., & Baker, D. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00159-9 · Cited by 22
Self-citationQuais são e pra que servem os medicamentos à base de Cannabis?
Pamplona, F. A. (2014) · Revista da Biologia · doi:10.7594/revbio.13.01.05 · Cited by 20
“Este uso clínico é amparado por evidências anedóticas dos pacientes (Consroe et al., 1997), dados pré-clínicos (Baker et al., 2000) e estudos prévios de Fase II (Killestein et al., 2002, Wade et al., 2003).”
Background
Metadata
- Authors
- Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., & Layward, L.
- Venue
- Nature
- Published
- 2000-03
- Volume
- 404
- Issue
- 6773
- Pages
- 84-87
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2171143812
- Cited by
- 532
- References
- 18
- FWCI
- 23.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.